For Biosimilar Developers, Honeymoon May Be Over

Law360, New York (March 15, 2013, 7:16 PM EDT) -- Three years after the Affordable Care Act created a way for the U.S. Food and Drug Administration to approve biosimilars, regulatory and market uncertainty has curbed many drugmakers' hopes of cashing in on a new superlucrative market, with some now questioning whether developing a biosimilar will ever make good business sense.

Under the ACA, the FDA was instructed to create a pathway for approving biosimilars, also known as follow-on biologics, which are akin to generics for traditional, small-molecule drugs. Much of the impetus was to create...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.